LMR Partners’s United Therapeutics UTHR Stock Holding History

LMR Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.12M	Sell	3,911 -12,525	-76%	-$7.05M	0.01%	882
2026 Q1	$9.75M	Buy	16,436 +1,089	+7%	+$542K	0.02%	445
2025 Q4	$7.48M	Buy	+15,347	New	+$7.15M	0.01%	475
2023 Q1	–	Sell	-9,455	Closed	-$2.63M	–	1170
2022 Q4	$2.63M	Buy	9,455 +7,841	+486%	+$1.98M	0.05%	428
2022 Q3	$338K	Sell	1,614 -1,094	-40%	-$245K	0.01%	945
2022 Q2	$638K	Buy	+2,708	New	+$551K	0.01%	858
2019 Q3	–	Sell	-26,064	Closed	-$2.04M	–	523
2019 Q2	$2.04M	Buy	+26,064	New	+$2.44M	0.07%	129
2015 Q2	–	Sell	-37,561	Closed	-$6.48M	–	606
2015 Q1	$6.48M	Buy	+37,561	New	+$5.73M	0.9%	23

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

LMR Partners's UTHR Position: Q2 2026 in Review

LMR Partners reduced its United Therapeutics (UTHR) stake by 76% in Q2 2026, selling an estimated $7.05M and leaving 3,911 shares worth $2.12M. The position accounts for 0.01% of the portfolio, ranked #882.

LMR Partners first reported a position in UTHR in Q1 2015 and has held it in 8 quarters since. The position peaked at $9.75M in Q1 2026. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

LMR Partners held 3,911 shares of United Therapeutics worth $2.12M as of Q2 2026.
LMR Partners sold 12,525 United Therapeutics shares in Q2 2026, an estimated $7.05M.
United Therapeutics made up 0.01% of LMR Partners's portfolio in Q2 2026, its #882 holding.
LMR Partners first reported a position in United Therapeutics in Q1 2015 and has held it in 8 quarters since.
LMR Partners's United Therapeutics position peaked at $9.75M in Q1 2026.
882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.